BLOG / 🇮🇳 India / ma activity · · daily

India Merger Acquisition MCA Regulatory Filings — November 11, 2026

India MCA Merger & Acquisition Tracker

By Gunpowder Editorial ·

4 high priority 3 medium priority 7 total filings analysed

Executive Summary

The November 11, 2026 MCA filing batch reveals a market dominated by small-ticket strategic M&A and captive-supply investments rather than large transformative deals.

Six of seven filings are new, with the most material being Cupid Limited's mixed Q2 FY27 results (revenue +122% YoY, net profit +133% YoY) and its completion of a ₹331 crore warrant investment in Baazar Style Retail, signaling a pivot toward retail exposure. Alivus Life Sciences closed 65.01% of IQGEN-X Pharma, moving toward its 76% target, while GP Petroleums executed a ₹44.27 crore SPA for a 22.45% stake in Incubit Pipavav Terminal to secure tank storage infrastructure. A clear pattern of promoter-group open-market accumulation (Awfis, Worth Peripherals) and related-party subsidiary creation (Jeena Sikho) suggests insiders are positioning ahead of anticipated value unlocks. Cross-filing period comparisons show revenue growth ranging from +6.8% (Avaada Indsolar) to +122% (Cupid), with margin pressure evident in Cupid's expense surge and finance costs (+135% YoY). Overall, the batch skews neutral-to-positive, with materiality concentrated in Cupid (8/10) and Alivus (7/10).

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: M&A

Tracking the trend? Catch up on the prior India Merger Acquisition MCA Regulatory Filings digest from November 04, 2026.

Investment Signals (10)

  • ▲

    Revenue surged 122% YoY to ₹18,786.19 Lacs and net profit rose 133% YoY to ₹5,622.45 Lacs, but the inclusion of a ₹2,002.64 Lacs fair-value gain (vs nil in Q2 FY26) means core operating profit growth is lower; watch for sustainability

  • ▲

    Board approved conversion of remaining 56,00,000 warrants of Baazar Style Retail at ₹328.25 per warrant, completing a 1,01,00,000-warrant investment—signals confidence in retail turnaround and adds a mark-to-market catalyst

  • Completed acquisition of 65.01% of IQGEN-X Pharma for ₹7.36 crore (implied ~₹11.3 crore for 76% target), making it a subsidiary effective Nov 11, 2026; earnings accretion likely from Q3 FY27

  • ▲

    SPA to acquire 22.45% of Incubit Pipavav Terminal for up to ₹44.27 crore, with board nomination rights—secures strategic tank storage infrastructure at Pipavav, potentially reducing logistics costs and enhancing margin

  • Board approved 26% stake in Avaada Indsolar for ₹0.46 crore to meet captive-user requirements under Electricity Act, enabling dedicated renewable power and ESG benefits; target turnover grew 6.8% YoY to ₹490.03 Million in FY25-26

  • Promoter group purchased shares in open market and may acquire more; voluntary disclosure under SAST/PIT signals confidence, though no quantities disclosed—watch for further filings

  • Incorporated 60%-owned subsidiary Ayugenomics for ₹3 lakh to integrate genomics with Ayurveda; early-stage but aligns with precision-health trend and could attract niche re-rating [NEUTRAL/BULLISH]

  • Promoter group (MD Jayvir Chadha and Ganiv Chadha) acquired 559 shares in open market—tiny absolute size but consistent with routine accumulation; low signal value

  • ▲

    Total expenses more than doubled to ₹13,608.14 Lacs and finance costs jumped 135% YoY to ₹164.57 Lacs, indicating scaling pains and higher leverage; margin sustainability is key

  • ▲

    Other non-operating income fell to ₹108.27 Lacs from ₹578.26 Lacs YoY, removing a prior profit cushion; quality of earnings may be lower without one-off gains

Risk Flags (8)

  • Cupid Limited↓ [HIGH RISK]
    ▼

    Profit growth of 133% YoY is flattered by a ₹2,002.64 Lacs fair-value gain (vs nil prior year); excluding this, net profit would be ~₹3,619.81 Lacs, still up ~50% YoY but far less spectacular—risk of disappointment if gains reverse

  • Cupid Limited↓ [MEDIUM RISK]
    ▼

    Finance costs surged 135% YoY to ₹164.57 Lacs and total expenses more than doubled, suggesting the Baazar Style Retail warrant investment may be debt-funded; watch leverage ratios

  • GP Petroleums↓ [MEDIUM RISK]
    ▼

    Acquisition from promoter-group seller Mrs. Anita Goyal is a Related Party Transaction; despite arm's-length valuation, governance discount may apply and minority shareholders could question terms

  • Alivus Life Sciences↓ [MEDIUM RISK]
    ▼

    Only 65.01% of IQGEN-X acquired vs 76% target; remaining stake purchase could face valuation renegotiation or regulatory delays, leaving minority interests and potential consolidation complexity

  • Jeena Sikho Lifecare↓ [MEDIUM RISK]
    ▼

    New subsidiary Ayugenomics has no operating history, no turnover, and requires CDSCO/US FDA approvals; cash burn likely before any revenue, with related-party governance concerns (promoter as director)

  • ▼

    Investment in Avaada Indsolar is tiny (₹0.46 crore) but ties up management attention; renewable power supply may face execution delays, and 26% stake gives significant influence but not control—accounting treatment unclear

  • ▼

    Promoter buying without disclosed quantities or prices limits ability to gauge conviction; if purchases are small, signal value is low and could be window-dressing

  • ▼

    Promoter purchases of only 559 shares are immaterial and may be routine; no actionable insight, but watch for larger purchases if conviction grows

Opportunities (7)

  • Cupid Limited↓ (OPPORTUNITY)
    ◆

    If core revenue growth (excluding fair-value gain) sustains >50% YoY, current valuation may not reflect earnings power; watch Q3 FY27 results for confirmation and any further Baazar Style Retail mark-to-market gains

  • Alivus Life Sciences↓ (OPPORTUNITY)
    ◆

    IQGEN-X consolidation from Nov 11, 2026 will boost Q3 FY27 revenue; if IQGEN-X margins are accretive, EPS upgrade cycle possible; completion of 76% stake is a near-term catalyst

  • GP Petroleums↓ (OPPORTUNITY)
    ◆

    Strategic stake in Incubit Pipavav Terminal at ₹44.27 crore (22.45%) implies equity value of ~₹197 crore; if terminal utilization improves, GPPL could see re-rating and potential consolidation of IPTPL in future

  • EIH Associated Hotels↓ (OPPORTUNITY)
    ◆

    Captive renewable power via Avaada Indsolar could reduce energy costs (typically 10-15% of hotel operating costs) and enhance ESG scores; small capital outlay with potentially outsized operational benefit

  • Awfis Space Solutions↓ (OPPORTUNITY)
    ◆

    Promoter open-market purchases often precede positive developments; monitor for disclosure of quantities and any subsequent board changes or strategic announcements

  • Jeena Sikho Lifecare↓ (OPPORTUNITY)
    ◆

    Genomics-Ayurveda integration is a niche but growing field; if Ayugenomics secures patents or regulatory approvals (CDSCO/US FDA), it could unlock new revenue streams and partnerships, especially in Japan

  • Worth Peripherals↓ (OPPORTUNITY)
    ◆

    Promoter accumulation, albeit small, may signal confidence in packaging sector turnaround; watch for larger purchases or order wins

Sector Themes (5)

  • Small-Ticket Strategic M&A Dominates
    ◆

    6 of 7 deals are below ₹50 crore, with 3 involving related parties or promoter groups—suggesting companies are using M&A for captive supply (EIH, GP Petroleums) and niche expansion (Jeena Sikho) rather than transformational bets [IMPLICATION: focus on execution and governance]

  • Promoter Accumulation Signals Conviction
    ◆

    Awfis and Worth Peripherals both disclosed promoter open-market purchases on the same day; while sizes vary, the voluntary nature of Awfis's disclosure hints at confidence, whereas Worth's tiny purchase is routine [IMPLICATION: watch for follow-through buying]

  • Revenue Growth Outliers
    ◆

    Cupid (+122% YoY) and Avaada Indsolar (+6.8% YoY) bracket a wide range; Cupid's growth is partly inorganic/fair-value driven, while Avaada's is steady—suggesting disparate sector trajectories (consumer vs renewable) [IMPLICATION: verify quality of growth]

  • Margin Pressure from Scaling
    ◆

    Cupid's total expenses more than doubled and finance costs surged 135% YoY, highlighting that rapid growth can strain profitability; similar patterns may emerge in other high-growth small caps [IMPLICATION: monitor operating leverage]

  • Captive Supply Investments on the Rise
    ◆

    EIH (renewable power) and GP Petroleums (tank storage) both invested for captive use, driven by regulatory requirements (Electricity Act) or operational efficiency—a trend likely to continue as companies seek cost control [IMPLICATION: look for similar announcements in hospitality and logistics]

Watch List (7)

  • Q3 FY27 results (likely Feb 2027) will reveal if 122% revenue growth sustains without fair-value gains; watch finance costs and Baazar Style Retail mark-to-market [DATE: Feb 2027]

  • Completion of remaining 10.99% stake in IQGEN-X to reach 76% target; any delay or renegotiation could impact sentiment [DATE: H1 2027]

  • Closing of SPA tranches over one year; watch for board nomination and any further stake increase; also monitor RPT approval process [DATE: ongoing through Nov 2027]

  • Completion of Avaada Indsolar investment by March 2027; watch for power purchase agreement details and cost savings quantification [DATE: March 2027]

  • Further disclosures under SAST/PIT if promoter purchases exceed thresholds; watch for quantities and any strategic announcements [DATE: ongoing]

  • Ayugenomics regulatory milestones (CDSCO/US FDA filings) and patent applications; any partnership announcements in Japan [DATE: 2027]

  • Any larger promoter purchases or order wins that could signal a turnaround; currently low materiality [DATE: ongoing]

Filing Analyses (7)
Jeena Sikho Lifecare Limited Merger/Acquisition neutral materiality 4/10

11-11-2026

Jeena Sikho Lifecare Limited incorporated a new subsidiary, Ayugenomics Private Limited, on 11th November 2026, acquiring a 60% controlling stake (30,000 equity shares of ₹10 each) for ₹3,00,000 in cash. The new entity, focused on integrating genomics and omics sciences with Ayurveda and AYUSH systems, is newly incorporated with no operating history or turnover, so it contributes no revenue currently. The transaction is a related-party arrangement as promoter/MD Manish Grover also serves as Director of the subsidiary, though shares were subscribed at arm's length (face value).

  • · Subsidiary CIN: U72100DC2026PTC476416; incorporated in India under Companies Act, 2013
  • · Ayugenomics has not commenced business operations and has no operating history or turnover
  • · Business scope includes seeking patents and regulatory approvals in India and abroad, including CDSCO and US FDA, and targeting markets such as Japan
  • · No specific governmental or regulatory approvals identified as presently required for the incorporation
  • · Shares subscribed at arm's length price (face value); consideration paid via cash through banking channels
  • · Intimation follows an earlier disclosure dated November 04, 2026
Awfis Space Solutions Limited Merger/Acquisition neutral materiality 3/10

11-11-2026

Awfis Space Solutions disclosed that certain members of its Promoter/Promoter Group purchased equity shares of the company from the open market and may acquire additional shares in the future. The company stated the purchases comply with SEBI SAST 2011 and PIT 2015 regulations, remain within prescribed disclosure limits, and do not trigger open offer obligations; the disclosure was made voluntarily as a good-governance measure. No share quantities, transaction values, or resulting shareholding percentages were disclosed in the filing.

  • · NSE Scrip Symbol: AWFIS; BSE Scrip Code: 544181; ISIN: INE108V01019
  • · Filing signed and digitally dated November 11, 2026 at 16:30:20 +05'30'
  • · Company commits to post-transaction disclosures under Regulation 29 of SEBI SAST Regulations 2011 and Regulation 7(2) of SEBI PIT Regulations 2015
  • · Registered office: C-28-29, Kissan Bhawan, Qutab Institutional Area, New Delhi – 110016; CIN: L74999DL2014PLC274236
  • · No number of shares acquired, price, or post-acquisition promoter shareholding was disclosed
EIH Associated Hotels Limited Merger/Acquisition positive materiality 4/10

11-11-2026

EIH Associated Hotels Limited's Board approved on 11th November 2026 an investment of up to 26% of the paid-up capital of M/s Avaada Indsolar Private Limited, a renewable power developer, at Rs. 10 per share for a maximum of Rs. 0.46 crores, to be completed for cash by March 2027. The stake is driven by captive-user requirements under the Electricity Act, 2003 and Electricity Rules, 2005 (minimum 26% equity holding in the SPV), enabling dedicated renewable power supply for hotel operations with cost savings and ESG benefits. The target's turnover rose to Rs. 490.03 Million in FY 25-26 from Rs. 458.72 Million in FY 24-25 (+6.8%), while FY 23-24 stood at Rs. 80.14 Million; the transaction is not a related party transaction and requires no governmental or regulatory approvals.

  • · Target entity Avaada Indsolar Private Limited was incorporated on 29th June 2021 under the Companies Act 2013.
  • · The acquisition is not a related party transaction and promoter/promoter group/group companies have no interest in the target.
  • · No governmental or regulatory approvals are required for the acquisition.
  • · Investment is structured as cash consideration, not a share swap.
  • · The 26% stake corresponds to a contract capacity of 1 MWac / 1.3 MWdc solar.
  • · Target turnover growth decelerated sharply to 6.8% in FY 25-26 from the prior year's 472.4% jump.
Alivus Life Sciences Limited Merger/Acquisition positive materiality 7/10

11-11-2026

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has completed the acquisition of 7,36,096 equity shares representing 65.01% of the issued and paid-up equity share capital of IQGEN-X Pharma Private Limited, making IQGEN-X a subsidiary effective November 11, 2026. This follows the share purchase agreement dated August 18, 2026 to acquire a 76% stake, with the remaining share capital to be acquired in due course. The transaction is a step toward the originally targeted 76% holding, of which 65.01% has now closed.

  • · IQGEN-X Pharma Private Limited became a subsidiary of Alivus effective November 11, 2026
  • · The remaining share capital of IQGEN-X will be acquired in due course to reach the 76% target
  • · Original share purchase agreement was disclosed via letter dated August 18, 2026
  • · Scrip Code: 543322; Scrip Name: ALIVUS
  • · Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Cupid Limited Merger/Acquisition mixed materiality 8/10

11-11-2026

Cupid Limited's Board approved unaudited standalone and consolidated results for Q2/H1 FY27, with standalone revenue from operations surging 122% YoY to ₹18,786.19 Lacs (from ₹8,442.99 Lacs) and net profit rising 133% YoY to ₹5,622.45 Lacs, aided by a ₹2,002.64 Lacs fair-value gain on investments. However, total expenses more than doubled to ₹13,608.14 Lacs and finance costs jumped 135% YoY to ₹164.57 Lacs, while other non-operating income fell to ₹108.27 Lacs from ₹578.26 Lacs. Separately, the Board approved conversion of the remaining 56,00,000 outstanding warrants of Baazar Style Retail Limited at ₹328.25 per warrant, completing its 1,01,00,000-warrant investment.

  • · Total income rose 132% YoY to ₹20,897.10 Lacs in Q2 FY27 from ₹9,021.25 Lacs, partly boosted by a ₹2,002.64 Lacs fair-value gain versus nil in Q2 FY26
  • · Purchase of stock-in-trade jumped to ₹4,981.93 Lacs from ₹1,018.62 Lacs YoY, and cost of material consumed rose to ₹4,635.65 Lacs from ₹2,242.19 Lacs
  • · Employee benefit expenses increased to ₹1,011.21 Lacs from ₹787.88 Lacs YoY
  • · Cash and cash equivalents fell sharply to ₹34.88 Lacs as at 30.09.2026 from ₹16,866.74 Lacs at 31.03.2026, with net cash used in investing activities of ₹29,908.49 Lacs (including ₹22,499.93 Lacs increase in non-current investments)
  • · Non-current investments rose to ₹31,913.70 Lacs from ₹7,486.94 Lacs; capital work in progress rose to ₹10,037.55 Lacs from ₹2,537.83 Lacs
  • · Borrowings increased to ₹3,882.21 Lacs non-current and ₹6,862.45 Lacs current, versus ₹1,216.54 Lacs and ₹3,880.61 Lacs respectively
  • · Trade receivables rose to ₹15,233.33 Lacs from ₹10,079.19 Lacs as at 31.03.2026
  • · Limited Review Report issued by Chaturvedi Sohan & Co. (FRN 118424W) with no material misstatement noted; UDIN 26106403WCORJX3005
  • · Board meeting held 04:30 PM to 05:00 PM on November 11, 2026
GP Petroleums Limited Merger/Acquisition neutral materiality 6/10

11-11-2026

GP Petroleums Limited executed a Share Purchase Agreement on November 11, 2026, to acquire a 22.45% stake in Incubit Pipavav Terminal Private Limited (formerly Gulf Petrochem (India) Private Limited) for an aggregate consideration of up to ₹44,26,97,141 (Rupees Forty-Four Crore Twenty-Six Lakh Ninety-Seven Thousand One Hundred and Forty-One), payable in one or more tranches over one year. The deal is a strategic investment to strengthen operational presence at Pipavav and access IPTPL's tank storage/rental space and terminal infrastructure, with GPPL entitled to nominate director(s) to IPTPL's Board. Notably, the purchase from Mrs. Anita Goyal constitutes a Related Party Transaction (promoter group) undertaken on an arm's length basis with an independent valuation report, while the purchase from Incubit Holding Pte. Ltd. is not an RPT; the Company currently holds nil shares in IPTPL.

  • · Selling shareholders are Incubit Holding Pte. Ltd. and Mrs. Anita Goyal (collectively)
  • · Acquisition from Incubit Holding Pte. Ltd. does not constitute a Related Party Transaction
  • · Acquisition from Mrs. Anita Goyal is an RPT as she is part of the promoter group, done at arm's length with independent valuation report
  • · GPPL held nil shareholding in IPTPL prior to the agreement
  • · Disclosure made under Regulation 30 and Part A of Schedule III of SEBI LODR Regulations, 2015, read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (updated January 30, 2026)
  • · Filing references prior outcome dated October 13, 2026 regarding the proposed acquisition
  • · No shares issued to counterparties (issue price/class: Not Applicable)
  • · BSE Scrip Code: 532543; NSE Symbol: GULFPETRO
Worth Peripherals Limited Merger/Acquisition neutral materiality 2/10

11-11-2026

Worth Peripherals Limited disclosed under Regulation 30 of SEBI LODR that promoter group members acquired shares through open market transactions: Managing Director Jayvir Chadha acquired 350 equity shares and Ganiv Chadha acquired 209 equity shares. The company stated both acquisitions are within prescribed limits under SEBI PIT and SAST Regulations, with no disclosure threshold triggered. The transaction size is very small (559 shares combined) and represents routine promoter-group share accumulation rather than a change of control.

  • · Filing made under Regulation 30 of SEBI (LODR) Regulations, 2015
  • · Company CIN: L67120MP1996PLC010808; NSE Symbol: WORTHPERI; BSE Scrip Code: 544577
  • · Acquisitions stated to be within limits under SEBI (PIT) Regulations, 2015 and SEBI (SAST) Regulations, 2011
  • · No disclosure threshold or limit was triggered by these acquisitions
  • · Company undertakes to intimate exchanges if future acquisitions trigger disclosure thresholds
  • · Filing dated November 11, 2026, signed digitally by Tushar Batham at 11:43:00 +05:30

Get daily alerts with 10 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 7 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: India Merger Acquisition MCA Regulatory Filings

🇮🇳 More from India

View all →